GLP-1 Drugs May Reduce Risk of Substance Use Disorders
Share
GLP-1 receptor agonists are medicines commonly used to treat type 2 diabetes and help with weight loss. Examples include semaglutide, liraglutide, and dulaglutide. Recently, scientists have started exploring another possible benefit of these drugs. New research suggests they may also reduce the risk of substance use disorders such as alcohol, nicotine, or opioid addiction.
A large study of US veterans with type 2 diabetes looked at whether people taking GLP-1 receptor agonists had a different risk of developing substance use disorders compared with those taking another diabetes drug class called SGLT-2 inhibitors. The findings were surprising and may open the door to new ways of preventing and treating addiction.
What Are GLP-1 Receptor Agonists?
GLP-1 receptor agonists are medications that mimic a hormone called glucagon-like peptide-1. This hormone helps control blood sugar levels after eating. It works by increasing insulin release, slowing stomach emptying, and reducing appetite.
Because of these effects, GLP-1 drugs are widely used for people with type 2 diabetes and obesity. Many patients also lose significant weight while using them.
However, researchers have discovered that GLP-1 receptors are also present in parts of the brain that control reward and motivation. These areas influence cravings and addictive behaviors. This raised an interesting question: could these drugs also reduce the risk of addiction?
How the Study Was Conducted
Researchers analyzed health records from over 600,000 US veterans with type 2 diabetes. Participants were followed for up to three years.
The study compared two groups:
- People who started a GLP-1 receptor agonist
- People who started an SGLT-2 inhibitor
The researchers looked at whether participants developed substance use disorders involving alcohol, cannabis, cocaine, nicotine, opioids, or other substances. They also examined outcomes in people who already had a substance use disorder.
This type of research uses real-world healthcare data to identify patterns and potential health benefits of medications.
Lower Risk of Developing Substance Use Disorders
The study found that people taking GLP-1 receptor agonists had a lower risk of developing several types of substance use disorders compared with those taking SGLT-2 inhibitors.
For example, the risk was lower for:
- Alcohol use disorder
- Cannabis use disorder
- Cocaine use disorder
- Nicotine use disorder
- Opioid use disorder
Overall, GLP-1 users had about a 14 percent lower risk of developing any substance use disorder during the follow-up period.
These findings suggest that GLP-1 drugs may influence brain pathways related to addiction and reward.
Benefits for People With Existing Addiction
The researchers also studied people who already had a substance use disorder before starting treatment.
In this group, GLP-1 receptor agonists were linked with lower risks of several serious outcomes, including:
- Emergency department visits related to substance use
- Hospital admissions related to substance use
- Drug overdoses
- Suicidal thoughts or attempts
- Death related to substance use
For example, the risk of substance use related emergency department visits was significantly lower among people taking GLP-1 drugs.
This suggests the medications might not only prevent addiction but could also improve outcomes for people already struggling with it.
Why These Drugs Might Reduce Cravings
Scientists believe GLP-1 drugs may affect the brain’s reward system. Certain brain regions release dopamine when people consume addictive substances such as alcohol or nicotine.
GLP-1 signaling appears to influence these pathways and may reduce the rewarding effects of drugs and alcohol. As a result, cravings may become weaker.
Animal studies have shown similar effects. Animals given GLP-1 medications often consume less alcohol or nicotine compared with untreated animals.
However, the exact mechanism is still being studied.
Important Limitations
Although the results are promising, this study has some limitations.
First, it was an observational study. This means researchers analyzed existing data rather than conducting a randomized clinical trial. Because of this, the study cannot prove that GLP-1 drugs directly cause the reduction in substance use disorders.
Second, the population consisted mostly of older male veterans. The results may not apply equally to women or younger populations.
Finally, more clinical trials are needed to confirm whether GLP-1 medications can be used specifically for addiction treatment.
What This Means for the Future
GLP-1 receptor agonists are already widely used for diabetes and weight management. If future studies confirm these findings, these drugs may also play a role in addiction prevention or treatment.
Researchers are now exploring whether GLP-1 medications could help people reduce alcohol intake, quit smoking, or manage other addictive behaviors.
While it is too early to prescribe these drugs solely for addiction, the research highlights an exciting new area of medicine that connects metabolism, brain function, and behavior.
